DEXFENFLURAMINE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN OBESITY

被引:115
作者
MCTAVISH, D
HEEL, RC
机构
[1] Adis International Limited, Auckland, 41 Centorian Drive, Private Bag 65901, Mairangi Bay
关键词
D O I
10.2165/00003495-199243050-00007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dexfenfluramine stimulates serotoninergic activity by inhibiting serotonin reuptake into presynaptic neurons and by enhancing its release into brain synapses. Based on the serotonin hypothesis of appetite control these effects would be expected to reduce food intake and thus bodyweight. Studies in animal models and severely overweight patients have confirmed the effectiveness of dexfenfluramine as a weight-reducing agent which appears to be well tolerated. Permanent weight loss is the goal of weight-reducing strategies and, based on current clinical evidence, dexfenfluramine appears to exert a weight reducing effect over periods of up to 12 months without development of tolerance, a problem that has limited the long term use of other pharmacological agents used in the treatment of this disorder. Dexfenfluramine facilitated weight loss in patients who had not responded satisfactorily to other weight-reducing strategies, prevented relapse in those patients who had achieved weight reduction by other methods, and corrected disturbed eating patterns (and therefore reduced weight gain) in small studies involving patients with premenstrual syndrome, seasonal affective disorder and nicotine withdrawal syndrome. Follow-up of the longest study reported with dexfenfluramine suggests that continued therapy is required in severely overweight patients if weight loss is to be maintained. Dexfenfluramine has not been directly compared with nonpharmacological measures of weight control such as behaviour modification or exercise programmes. The decision that pharmacological means are indicated in overweight patients must be highly individualised, and must consider the many complex factors that often contribute to overweight states, as well as the anticipated magnitude of drug effect. Despite such a cautionary note, and the expected need (at this stage of its development) for an expanded clinical study programme in certain areas, dexfenfluramine is a clear advance in the pharmacological approach to improved management of overweight individuals.
引用
收藏
页码:713 / 733
页数:21
相关论文
共 87 条
[1]   DECREASED INCORPORATION OF GLUCOSE INTO LIPIDS AND INCREASED LACTATE PRODUCTION BY ADIPOSE-TISSUE AFTER LONG-TERM TREATMENT OF RATS WITH D-FENFLURAMINE [J].
ALSIENI, AII ;
PLESTED, CP ;
ROLLAND, Y ;
BRINDLEY, DN .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (21) :3661-3667
[2]   PULMONARY-HYPERTENSION AND DEXFENFLURAMINE [J].
ATANASSOFF, PG ;
WEISS, BM ;
SCHMID, ER ;
TORNIC, M .
LANCET, 1992, 339 (8790) :436-436
[3]   EATING CAUSED BY NEUROPEPTIDE-Y INJECTION IN THE PARAVENTRICULAR HYPOTHALAMUS - RESPONSE TO (+)-FENFLURAMINE AND (+)-AMPHETAMINE IN RATS [J].
BENDOTTI, C ;
GARATTINI, S ;
SAMANIN, R .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1987, 39 (11) :900-903
[4]   THE ROLE OF PUTATIVE 5-HT1A AND 5-HT1B RECEPTORS IN THE CONTROL OF FEEDING IN RATS [J].
BENDOTTI, C ;
SAMANIN, R .
LIFE SCIENCES, 1987, 41 (05) :635-642
[5]   8-HYDROXY-2-(DI-NORMAL-PROPYLAMINO)TETRALIN(8-OH-DPAT) ELICITS EATING IN FREE-FEEDING RATS BY ACTING ON CENTRAL SEROTONIN NEURONS [J].
BENDOTTI, C ;
SAMANIN, R .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 121 (01) :147-150
[6]  
BEYNEN AC, 1986, NUTR REP INT, V33, P491
[7]  
BLUNDELL JE, 1988, CLIN NEUROPHARMACOL, V11, pS121
[8]   SEROTONIN MANIPULATIONS AND THE STRUCTURE OF FEEDING-BEHAVIOR [J].
BLUNDELL, JE .
APPETITE, 1986, 7 :39-56
[9]  
BLUNDELL JE, 1985, METABOLIC COMPLICATI
[10]   D-FENFLURAMINE AND D-NORFENFLURAMINE REDUCE FOOD-INTAKE BY ACTING ON DIFFERENT SEROTONIN MECHANISMS IN THE RAT-BRAIN [J].
BORSINI, F ;
BENDOTTI, C ;
ALEOTTI, A ;
SAMANIN, R ;
GARATTINI, S .
PHARMACOLOGICAL RESEARCH COMMUNICATIONS, 1982, 14 (07) :671-678